期刊文献+

舒血宁合并奥氮平治疗慢性精神分裂症的对照研究 被引量:6

Comparative Study of Olanzapine Combined with Shuxuening Versus Olanzapine in the Treatment of Chronic Schizophrenia Patients
原文传递
导出
摘要 目的比较舒血宁合并奥氮平与单用奥氮平治疗慢性精神分裂症的疗效。方法将2009年1月—2011年6月我院86例慢性精神分裂症患者分为奥氮平合并用舒血宁治疗组(联合用药组)和单纯服奥氮平治疗组(对照组),各43例。选用阳性与阴性症状评定量表(PANSS)和精神药物不良反应量表(TESS)评定临床疗效和不良反应。评价治疗前和治疗后第4,8,12周的病情变化。结果联合用药组对慢性精神分裂症的有效率为34.88%,而对照组的有效率为20.93%,两组比较差异有统计学意义(P<0.05)。两组不良反应比较:头晕、嗜睡、心动过速、体重增加方面差异有统计学意义(P<0.05)。结论对慢性精神分裂症患者采用奥氮平联合舒血宁治疗比单用奥氮平疗效更好,且不良反应更小。 OBJECTIVE To compare the efficacy and safety of olanzapine combined with Shuxuening versus olanzapine in the treatment of chronic schizophrenia inpatients. METHODS Eighty-six patients were recruited in our hospital and randomly assigned to receive olanzapine combined with Shuxuening, or olanzapine for up to 12 weeks. All patients were checked by the scale of PANSS and TESS before treatment and at 4, 8 and 12 weeks during treatment. RESULTS There were statistically significant differences between the trial group and the control group in efficacy and adverse reactions(P〈0.05). The effective rate of the research group was 34.88%, the control group was 20.93%. The incidence rates of adverse reactions in research group were lower than those in control group in dizziness, drowsiness, tachycardia and weight gain. CONCLUSION Olanzapine combined with Shuxuening may be more efficacious than olanzapine lonely in the treatment of chronic schizophrenia patients, and be much lower in adverse reactions.
出处 《中国现代应用药学》 CAS CSCD 2012年第6期550-554,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 舒血宁 奥氮平 慢性精神分裂症 Shuxuening olanzapine chronic schizophrenia
  • 引文网络
  • 相关文献

参考文献5

二级参考文献25

  • 1罗和春,沈渔邨,钟红文,贾云奎,谭春香,崔玉华,孟凡强,杨旭东,刘建成,朱连成,李兵,张惠敏,孙志伟,王丽娟,朱明霞,朱美兰,朱香兰,赵学英,于欣.舒血宁合并抗精神病药物治疗慢性精神分裂症的临床疗效分析[J].中华精神科杂志,1996,29(1):31-34. 被引量:24
  • 2向荣.过氧化脂质硫代巴比妥酸分光光度法的改进[J].生物化学与生物物理进展,1990,17(3):241-243.
  • 3夏奕明 朱莲珍.血和组织谷胱甘肽过氧化物酶活力的测定方法:I.DTNB直接法[J].卫生研究,1987,16:29-33.
  • 4王希林,中国心理卫生杂志,1995年,1期,封二页
  • 5祁福生,中华医学会精神科学会成立暨第一次学术会议论文摘要汇编,1994年
  • 6王焕林,中华神经精神科杂志,1994年,27卷,6页
  • 7沈渔--,精神病学(第3版),1994年
  • 8王焕林,中华神经精神科杂志,1992年,25卷,68页
  • 9王甫文,新药与临床,1991年,10卷,331页
  • 10杨德森,中国精神疾病诊断标准与案例,1989年

共引文献116

同被引文献43

  • 1程艮,李峥.精神分裂症患者药物依从性影响因素的研究进展[J].中华护理杂志,2005,40(9):699-701. 被引量:59
  • 2何燕玲.阳性与阴性症状量表[M].北京:中国心理卫生杂志社,1999,(增刊):267-276.
  • 3Singh V, Singh SP, Chan K. Review and meta-anaiysis of us- age of ginkgo as adjunct therapy in chronic schizophrenia [J]. Int J Neuropsychopharmacol, 2010,13 (2) : 257- 271.
  • 4Schatzberg AF.New approach to managing psychotic depression[J].J Clin Psychiatry,2003,64(Suppl 1):19-23.
  • 5Foruito A, Yoon J, Zalesky A, et al. General and specific functional connectivity disturbances in first- episode schizophrenia during cognitive control performance[J]. Biol Psychiatry, 2011, 70(1): 64- 72. doi:lO.lO16/j.biopsych,2011.02.019.
  • 6Carts VS, Catts SV, Mcgrath JJ, et al. Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines[J]. Schizophrenia Research, 2006, 84(1):20-28.doi:10,1016/j.schres,2006.03.016.
  • 7Bai O, Wei Z, Lu W, et al. Protective effects of atypical antipsychot- ic drugs on PC12 ceils after serum withdrawal[J]. Journal of Neuro- science Research, 2002, 69(2): 278-283.
  • 8Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus [J]. Brain Research, 2004, 1010(1): 81-86. doi: 10,1002/jnr. 10290.
  • 9郭荣.中医药治疗抗精神病药物所致闭经的临床体会[J].辽宁中医杂志,2008,35(9):1381-1382. 被引量:5
  • 10全瑞国,李秉泉,李丽琴,王东明,宋培义,陈富仁.黄芪注射液辅助治疗对慢性精神分裂症患者生物学的影响及疗效观察[J].中国药房,2009,20(9):701-703. 被引量:4

引证文献6

二级引证文献31

;
使用帮助 返回顶部